Evidence map›Paper›PMID 41923881›Full record

ArticleFrontiers in genetics2026

Achieving bottom-up ethical, legal, and societal implications and responsible research and innovation in the synthetic biology research community from the Japanese context.

Makiko Matsuo, Katsumi Hagino, Saya Kawata, Tomohisa Hasunuma, Kohsuke Honda

Abstract read
In one paragraph

Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Makiko MatsuoGraduate School of Public Policy, The University of Tokyo, Tokyo, Japan.
Katsumi HaginoDepartment of Bacteriology, University of Wisconsin-Madison, Madison, WI, United States.
Saya KawataGraduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
Tomohisa HasunumaEngineering Biology Research Center, Kobe University, Kobe, Japan.
Kohsuke HondaInternational Center for Biotechnology, Osaka University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomanufacturing and synthetic biology are increasingly seen as essential to realizing a global bioeconomy. Within the broader trends in science and technology policy, the emphasis on foresight and addressing societal challenges has been growing. Addressing ethical, legal, and social implications/issues (ELSI) has become a prerequisite for responding to these trends in several countries, including Japan. This paper focuses on a specific aspect of ELSI, rulemaking, which is attracting increasing attention in the policy context. It highlights the lack of sufficient bottom-up initiatives from the academic research and development (R&D) community in this area and identifies three key areas for action that should be considered: (1) Advancing R&D informed by technological trends as well as policy and societal developments, (2) engaging in proactive deliberation to ensure safety and security, and (3) contributing to discussions on standardization. Moving forward, these recommendations must be elaborated on through discussions with universities, academic societies, the government, funding agencies, industries, and other stakeholders.

Indexed as

ELSIengineering biologygovernanceJapanRRIsynthetic biology

Identifiers

PMID41923881
PMCPMC13038228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.